Dr Mark Eccleston is polymer chemist and biotechnology entrepreneur with over 30 years experience working in translation science in both drug and biomarker development.
He is an inventor on over 30 patents ranging from CAR-T cell therapy to nucleosome enrichment as well as biodegradable chewing gum.
Mark is the Managing Director of OncoLytika Ltd, a UK based technology consultancy company with a successful track record of securing grant funding, strategic business development and client project management. He is a scientific founder of several companies, including Volition, where he currently serves as an independent scientific advisor supporting Nu.Q®️ Discover.
Mark also serves on the Scientific and Commercial Advisory boards of ValiRx Plc whose focus is progressing early-stage assets through the value chain and also supports commercialization activities for its parent company and translational Contract Research Organization, Inaphaea.
In addition to his commercial activities, Mark has supervised multiple PhD and Masters students at various universities, including the Open University, Greenwich University and DKFZ in Germany. He also serves as an external advisor to the Open University, contributing to modules focused on employability of biosciences graduates and employer expectations from graduates in terms of bioinformatics training.
